Shots:

• Eris Lifesciences acquired Novartis’ novel therapy Zomelis for $13M (~INR 93 crore) and will initiate the commercialization of product from Dec 10- 2019 in India
• The acquisition of Zomelis will robust Eris Lifesciences’ presence with the enhancement of its diabetic portfolio in India and allow Eris to strengthen its products offering for patients with diabetes
•  Zomelis is a therapy to treat type 2 diabetes and is the first innovator pharmaceutical product trademark acquisition by Eris. Additionally- Eris acquired Strides Shasun’ branded business portfolio to strengthen its footprints in the CNS segment for INR500 crore

Click here to­ read full press release/ article | Ref: Business Standards | Image: 1mg